Aim: Whether CRP also affects EC migration, however, has yet to be determined. The present study investigates how long-term exposure to CRP interacts with vascular endothelial growth factor (VEGF) -induced EC migration. Methods and Results: Using a Transwell chamber migration assay, VEGF (20 ng/mL, 5 h incubation) -induced migration of human umbilical vein EC was significantly inhibited in cells pretreated with CRP (10 g/mL) for 24 h by more than 75%. EC migration in response to VEGF is known to require activation of the proteinkinase B (Akt)/endothelial NO synthase (eNOS)-and the extracellular signal-regulated protein kinase 1/2 (ERK1/2) pathway. We therefore investigated the long-term effects of CRP on these signalling events. Immunoblotting with phosphospecific antibodies revealed rapid and transient activation/phosphorylation of the protein kinase Akt within 20 minutes after stimulation with VEGF, which was inhibited by 86% in EC pretreated with CRP (10 g/mL, 24 h, p 0.05). Subsequent VEGF-induced phosphorylation of eNOS downstream of Akt was completely inhibited in CRP-treated EC. In contrast, CRP-pretreatment did not affect VEGF-induced phosphorylation of ERK1/2. Interestingly, stimulation of EC with CRP for 16 − 24 h induced marked expression of the phosphatase and tensin homolog (PTEN), which functions as a negative regulator of phosphatidylinositol 3 kinase (PI3K) Akt signalling. Conclusion: The observed time course for CRP-mediated PTEN upregulation corresponds to the exposure time needed for inhibition of Akt phosphorylation and migration and may therefore constitute a potential mechanism by which CRP inhibits inducible Akt phosphorylation and EC migration.
Introduction
According to WHO statistics, cardiovascular diseases are among the most common causes of mortality worldwide and a leading cause of death in modern of cardiovascular events 5, 6) , plays an active role in promoting atherosclerosis 7) and may be associated with oxidative stress in lesion formation 8) . CRP is localized in human atherosclerotic lesions, where it induces the production of matrix-metalloproteinase 1 (MMP1) and thereby contributes to plaque instability 9, 10) . Serum levels of CRP have been shown to correlate with the occurrence of cardiovascular diseases 5, 7) .
However, despite an increasing number of clinical data and in vitro studies on the direct and indirect effects of CRP on the vasculature and its role in atherosclerotic lesion formation, there is still controversy regarding the clinical and pathogenic significance of CRP in these processes 11, 12) . One example is a study by Paul and coworkers, who reported enhanced atherosclerosis in apolipoprotein E knockout mice expressing transgenic human CRP 13) , whereas other studies by Dr. Pepys group found no such effect in the same animal model 14, 15) . Also, some authors ascribe a number of in vitro effects of recombinant CRP on proinflammatory proteins to contamination with bacterial products such as endotoxins 16) and consider that recombinant human CRP produced in bacteria as inappropriate and unsuitable for this kind of work 17, 18) . Although in some investigations, endotoxin contamination may have played a confounding role in the interpretation of CRP data, a recent study by Dasu et al. 19) on the effect of purified human CRP on human aortic endothelial cells reported inhibition of eNOS activity by CRP, which is not attributable to endotoxin contamination. Other in vitro studies in endothelial cells show that CRP promotes the expression of adhesion molecules 20) , plasminogen activator inhibitor-1 21) , chemokines and endothelin-1 21) , and decreases levels of endothelial NO synthase (eNOS) 22) . These cellular effects are potentially clinically relevant, since nitric oxide (NO) derived from eNOS is a key mediator in arterial vasodilatation, inhibits vascular smooth muscle cell proliferation, and promotes endothelial cell growth as well as migration and angiogenesis 23) . Dysregulation of NO is considered to be a critical step in the early development of atherogenesis 24, 25) . Experimental studies have reported that chronic exposure to CRP promotes apoptosis of human EC 22) and diminishes the reendothelialization following perivascular injury in mice 26) ; however, the mechanisms involved in these processes are not completely understood. A recent study by Singh and collegues showed that chronic exposure to CRP inhibits angiogenesis and also the proliferation of EC in response to vascular endothelial growth factor (VEGF) 27) . Reendothelialization and angiogenesis require endothelial cell proliferation and migration, which are both potently induced by VEGF in micro-and macrovascular endothelial cells 22, 28, 29) . VEGF acts via three different receptors: VEGF receptor (R) 1, -2 30) , and -3, which all belong to the superfamily of receptor tyrosine kinase receptors. VEGF receptors have been shown to mediate endothelial cell migration and proliferation through activation of the mitogen-activated protein kinase (MAPK)-and the proteinkinase B (Akt)/ eNOS-pathway 31) . Since VEGF-directed migration of endothelial cells plays a critical role in vascular repair, it was the aim of this study to understand whether chronic exposure to CRP affects endothelial cell migration and to elucidate the chemotactic signalling pathways that are involved.
Methods

Materials
Medium 199 Earle and fetal calf serum (FCS) were purchased from Seromed. VEGF, L-glutamine, antibiotics, HEPES, DMSO, gelatin, L--phosphatidylethanolamine, L--phosphatidylcholine, L--phosphatidyl-L-serine, sphingomyelin, and L--phosphatidylinositol-4,5-diphosphate were from Sigma. Hybond ECL nitrocellulose membrane, horseradish peroxidaselinked anti-rabbit antibody, as well as ECL Western blotting detection reagents were from Amersham Life Sciences. Culture plasticware was from Falcon. The MAPK-ERK1/2 kinase (MEK) inhibitor PD98059 and antibodies against Akt, phospho-Akt (Ser 473), phospho-eNOS (Ser 1177), ERK 1/2 and phospho-ERK 1/2 (Thr 202/Tyr 204) were purchased from New England BioLabs. The Akt inhibitor (1L-6-Hydroxymethyl-chiro-inositol 2-O-methyl-3-O-octadecycarbonate) was purchased from Alexis Biochemicals. Antibodies against eNOS and PTEN were obtained from Santa Cruz Biotechnology. Wortmannin was from Sigma-Aldrich. Highly purified CRP from human plasma (TriChem Resources Inc.) was free of endotoxin ( 0.05 ng/mL), as assessed by the limulus assay (BioWhittaker Europe). The CRP concentration used in the present study (10 g/mL) is within the range of CRP concentrations applied to human endothelial cells in other studies (5 − 50 g/ mL) 19, 32, 33) and corresponds to mildly elevated human plasma levels of CRP 12) . The cell death ELISA kit was purchased from Boehringer Mannheim.
Cell Culture
Human umbilical vein ECs (HUVEC) were prepared as described previously 34) . Cells were cultured in medium 199 Earle containing 20% FCS, 150 mmol/L HEPES, 100 U/mL penicillin, 100 g/mL streptomycin, 2 mmol/L glutamine, 10 ng/mL aFGF and 5 U/ mL heparin. Western blot and migration experiments were performed with medium 199 Earle containing 5% FCS (heat inactivated), 150 mmol/L HEPES, 100 U/mL penicillin, 100 g/mL streptomycin, and 2 mmol/L glutamine. The purity of EC cultures was verified by immunostaining with an antibody against CD31. For all data shown, each individual experiment represented in the n value was performed with an independent preparation of HUVEC. DMSO was used as a solvent for wortmannin, PD98059 and Akt inhibitor, whereas CRP and VEGF were dissolved in phosphate-buffered saline. DMSO was present at equal concentrations in all groups, including the control.
Western Blot Analysis
For protein analysis, early passaged (3 or less) HUVEC were grown to 60% to 70% confluency and then starved for 16 hours in 5% FCS/medium 199. For inhibitor studies, cells were pretreated for 8 to 24 hours with CRP (10 g/mL), or vehicle (5% FCS/ medium 199) alone, followed by the addition of VEGF (20 ng/mL). Western blot analysis was performed as described previously 35) . For immunoblotting, antibodies were used that recognize either PTEN or Akt, which is phosphorylated on serine 473, that is, "phospho Akt," eNOS, when phosphorylated on serine 1177, that is, "phospho eNOS," ERK1 or ERK2, which are phosphorylated on threonine 202 and tyrosine 204, that is, "phospho ERK1/2 MAPK," all Akt protein, independent of its phosphorylation state, that is, "total Akt," all eNOS protein, that is, "total eNOS," or all ERK1 and ERK2 proteins, that is, "total ERK1/2 MAPK." To control for equal protein concentrations, two gels from each group were loaded in parallel with the same protein samples and blotted for activated, phosphorylated proteins or total Akt, eNOS, or ERK1/2. The phosphorylation state of these signalling proteins in the presence of 5% FCS was not affected by any of the pharmacological inhibitors (data not shown).
Migration
HUVEC migration was examined in Transwell cell culture chambers with gelatin-coated polycarbonate membranes as described previously 35) . Cells were pretreated with VEGF (20 ng/mL), CRP (10 g/mL), or vehicle alone (5% FCS/medium 199) for 5 hours to the lower compartment. For inhibitor studies, all were either pretreated with CRP (10 g/mL) for 16 to 24 hours, or with PD98059 (10 − 30 mol/L), wortmannin (50 − 100 nmol/L), the Akt inhibitor (5 − 10 mol/L), or vehicle for 30 minutes at 37 . Inhibitors were added to both the upper and the lower compartments and were present throughout the experiment.
Experiments were performed in duplicate or triplicate and were repeated at least 3 times. Modified checkerboard analysis revealed that VEGF is chemotactic for HUVEC (data not shown).
Detection of Apoptosis
To examine apoptosis, subconfluent cell monolayers were made quiescent by incubation with 5% FCS/medium 199 for 16 h, followed by incubation with CRP (10 g/mL), or VEGF (20 ng/mL) in 5% FCS/medium 199 for 24 hours. Controls were kept in 5% FCS/medium 199. Samples were collected and cell death detection ELISA was performed according to the manufacturer's instructions. In brief, antihistone antibody containing coating buffer was added to the 96-well ELISA plates and incubated overnight at 4 . After recoating and incubation for 30 min at room temperature, the plates were rinsed 3 times. Sample solutions were added, incubated for 90 min and the plates were rinsed again. Bound nucleosomes were detected by the addition of anti-DNA-peroxidase monoclonal antibody, which was incubated for 90 min at room temperature. The plates were then rinsed and peroxidase activity was determined photometrically after color reaction with ABTS as a substrate. Optical density was measured with an ELISA reader at 405 nm. Three independent experiments were performed.
Statistics
Densitometry of Western blots was performed with the NIH Image program 1.60 for Macintosh. When appropriate, ANOVA testing with the Bonferroni post-hoc test was performed to compare differences between groups. Probability values 0.05 were considered significant.
Results
Chronic CRP Exposure Inhibits VEGF-Induced Endothelial Cell Migration
Previous studies have shown that VEGF acts as a potent migration factor on endothelial cells and it is known that a strong migration response occurs at a concentration of 20 ng/mL VEGF. We therefore examined the influence of chronic CRP exposure (10 g/ mL) on VEGF-directed endothelial cell migration using a Transwell migration chamber assay. We observed a profound increase in endothelial cell migration in response to VEGF, which was significantly inhibited by CRP in a time-dependent manner. Acute coincubation with CRP did not affect EC migration in response to VEGF. While preincubation with CRP for 16 hours caused a moderate inhibition of VEGF-induced EC migration ( 30.7 4,9%; n.s.), longer exposure to CRP markedly attenuated endothelial cell migration in response to VEGF ( 75,1 5,6% at 24 h, p 0,05 compared with VEGF alone) ( Fig. 1A) .
An earlier study reported that exposure to CRP could cause apoptosis in endothelial cells. To test the hypothesis that the observed effects of CRP on VEGFstimulated endothelial cell migration might be due to a CRP-mediated increase in programmed endothelial cell death, additional apoptosis experiments were performed. Endothelial cells were incubated for 24 hours with CRP (10 g/mL), or VEGF (20 ng/mL) in 5% FCS/medium 199, whereas controls were kept in 5% FCS/medium 199. Endothelial cells that had undergone apoptosis were then measured using a cell death ELISA. At the concentrations used, we did not observe any increase in apoptosis in CRP-or VEGFtreated endothelial cells as compared to controls (data not shown).
VEGF-Induced Migration is PI3K/AKT and ERK1/2 Dependent
The activation of Akt and its downstream signalling molecules, especially eNOS, is known as an important step in VEGF-induced migration of ECs 36) . The PI3K Akt pathway inhibitor wortmannin (0.05 and 0.1 mol/L) and the Akt inhibitor (1L-6-hydroxymethyl-chiro-inositol 2-O-methyl-3-O-octadecycar-bonate) were used to show that VEGF (20 ng/mL)directed migration depends on activation of the PI3K Akt pathway. Both pharmacological inhibitors significantly blocked VEGF-induced migration in a dosedependent manner (p 0.05) (Fig. 1B) . We next confirmed that VEGF-induced migration depends on activation of the ERK1/2 pathway using the pharmacological inhibitor PD98059 (10 and 30 mol/L). Blockade of the ERK1/2 pathway with PD98059 resulted in significant inhibition of EC migration towards VEGF ( 52, 2 11,2% at 10 mol/L, and 93,8 4,4% at 30 mol/L, p 0.05) (Fig. 1B) . None of the pharmacological inhibitors significantly affected the migration of unstimulated ECs, which were kept in 5% FCS (data not shown). Also, none of the pharmacological inhibitors caused any cytotoxic effects at the concentrations used. There was no evidence of cell detachment or loss of plasma membrane integrity, as evidenced by the uptake of trypan blue.
VEGF Induces the Transient Activation of Akt, eNOS and ERK1/2 in Endothelial Cells
VEGF has previously been reported to activate the PI3K Akt eNOS-as well as the ERK1/2 pathway via protein phosphorylation in different cell types. To corroborate our findings that the PI3K pathway inhibitor wortmannin, the Akt inhibitor 1L-6-Hydroxymethyl-chiro-inositol 2-O-methyl-3-O-octa- decycarbonate, and also the ERK1/2 pathway inhibitor PD98059 inhibited VEGF-induced chemotactic signaling in endothelial cells, we examined the effects of VEGF on the kinases involved. Using immunoblotting with phospho-specific antibodies against phosphorylated, activated Akt, we observed a profound upregulation of Akt activity, which peaked at 20 minutes (11.5-fold increase, Fig. 2A ) and returned to the baseline 60 minutes after stimulation with VEGF (20 ng/mL). The subsequent phosphorylation and activation of Akt´s downstream substrate eNOS were also assessed by immunoblotting with phospho-specific antibodies. Unstimulated cells in the control group exhibited low eNOS activity, as evidenced by the faint bands detected with phospho-specific antibodies. Stimulation with VEGF (20 ng/mL) induced the phos- Fig. 2B) . VEGF also induced a transient phosphorylation of ERK1/2, leading to a maximum increase with 5-fold upregulation 20 minutes after stimulation (Fig. 2C) . The amount of total Akt, eNOS or ERK1/2 protein was not affected by VEGF during the investigated time course. Neither wortmannin nor the Akt inhibitor had any effect on VEGF-induced ERK1/2 phosphorylation, and PD98059 did not affect Akt, or eNOS phosphorylation in response to VEGF at the concentrations used (data not shown). These results indicate that the PI3K Akt eNOS and the ERK1/2 pathway are two distinct signaling pathways that independently transmit Long-term exposure to CRP inhibits VEGF-induced signalling via AKT and eNOS. After preincubation with CRP (10 g/mL) for 0-24 hours, HUVEC were stimulated with VEGF (20 ng/mL), and samples were then immunoblotted for activated, phosphorylated Akt, total Akt, phosphorylated eNOS, or total eNOS.
(C) VEGF-stimulated ERK1/2 activation is not affected by CRP.
Exposure to CRP does not affect VEGF-induced ERK1/2 phosphorylation. HUVEC were preincubated with CRP as described in 3A and B. Samples were immunoblotted for activated, phosphorylated ERK1/2 and total ERK1/2. All Western blots and densitometries shown are representative of at least 3 experiments with different cell preparations. Densitometric data are expressed as the mean SEM. p 0.05 vs Control, p 0.05 vs VEGF alone.
Phospho-Akt
Total Akt chemotactic signals in response to VEGF (Fig. 4B) .
CRP inhibits VEGF-Induced Signalling Via Akt and eNOS
To determine whether CRP inhibited migration by targeting the PI3K Akt eNOS-or the ERK1/2 pathway, we investigated its effects on VEGF-induced Akt eNOS and ERK1/2 activation. EC were stimulated with VEGF for 20 minutes to test for maximal induction of Akt and ERK1/2 or for 30 minutes to achieve maximal eNOS phosphorylation. Whereas VEGF-induced phosphorylation of Akt and its downstream target eNOS was not visibly affected by acute coincubation with CRP, long-term preincubation with CRP for 24 hours markedly attenuated Akt phosphorylation by 86% (Fig. 3A) and completely abolished eNOS phosphorylation in response to VEGF (Fig. 3B) . In contrast, ERK1/2 activation in response to VEGF was not affected by CRP (Fig. 3C) .
Long-Term Exposure to CRP Upregulates PTEN Expression in Endothelial Cells
PTEN is a lipid phosphatase that antagonizes PI3K-mediated phosphorylation of Akt by dephosphorylating the D3 position of phosphatidylinositol (3, 4, 5) trisphosphate, which functions as a second messenger to activate Akt 37) . In accordance with that, a previous study reported the inhibition of VEGFinduced EC migration and angiogenesis by PTEN through blockade of the inducible phosphorylation of Akt 38) . These findings led us to investigate the effects of CRP on PTEN levels in EC. We found that longterm stimulation of quiescent EC with CRP caused marked upregulation of PTEN protein expression in these cells, leading to a 6.6-fold increase in PTEN protein levels after incubation for 24 hours (Fig. 4A) . The observed time course of CRP-mediated PTEN upregulation corresponds to the exposure time of EC to CRP of inhibit VEGF-induced Akt and eNOSphosphorylation and may therefore constitute a potential mechanism by which CRP inhibits Akt-/ eNOS-mediated EC migration (Fig. 4B) .
Discussion
The nonspecific acute-phase protein CRP is a pluripotent mediator of inflammation that participates in a variety of inflammatory processes. A vast number of studies underscore the deleterious role of inflammation in atherosclerotic lesion formation 1, 39) , and we know today that CRP supports atherogenesis 9) and is present in human atherosclerotic lesions 40) . CRP acts as a strong predictor of cardiovascular events and its levels correlate with the occurence of cardiovascular complications 5, 41) . The recently published JUPITER trial 42) showed that treatment with the cholesterin-synthase-enzyme inhibitor rosuvastatin reduces abnormally elevated CRP levels in patients, which coincides with a reduction of major cardiovascular events in this cohort. These results highlight the importance of pharmacological antiinflammatory strategies, which may constitute a useful approach in the prevention and therapy of cardiovascular diseases in the future.
In accordance with these clinical data, a number of animal and in vitro studies have demonstrated different CRP effects on the vasculature that potentially promote vascular lesion formation. This includes antiproliferative effects on endothelial cells, attenuated reendothelialization after carotid artery injury 26) , and impaired EPC-mediated angiogenesis 43) . CRP has also been reported to induce the expression of proinflammatory proteins in endothelial cells 21, 40, 44) and to downregulate endothelial NO synthase (eNOS) protein levels 22) . The potential of CRP to directly interact with endothelial cell signalling is further supported by a recent study from Tanigaki and collegues, who described the inhibition of insulin-induced eNOS activation by CRP via the immunoreceptor tyrosinebased inhibitin motif of FcgammaRIIB in endothelial cells 45) . These results point towards the specific interaction of CRP with endothelial signal transduction through activation of the immunoreceptor Fcgam-maRIIB. Although in our experiments, a consistent and significant inhibition of EC migration by CRP was observed, different results were obtained in a study recently published by Turu and colleagues, who found an increase in the migration, proliferation and tube-like structure formation in bovine aortic endothelial cells after CRP treatment 46) . Whether these different findings are related to the lower CRP concentrations used by Turu et al. (1 − 5 g/mL) 46) , or the different types of endothelial cells that were examined in these two studies, remains unclear and further research will help to elucidate the underlying causes.
Our study is the first to demonstrate that CRP inhibits VEGF-induced migration of endothelial cells via inhibition of the Akt eNOS signalling pathway. So far, the mechanisms and signalling pathways involved in EC migration are not completely understood. Migration itself is a complex endothelial response that involves chemotaxis, locomotion, and invasion, cellular functions that are regulated by a number of cytosolic and nuclear signalling events. Among the cytosolic signalling steps that participate in the migration process, several studies have recognized the Akt eNOS pathway as an important signalling cascade in VEGF-mediated EC migration 47, 48) . The chemoattractant-induced activation of Akt has been shown to induce reorganization of the actin/ myosin cytoskeleton and subsequent cell movement 48) . In addition, Akt has been reported to phosphorylate and activate endothelial nitric oxide synthase 47) , which probably contributes to angiogenesis through endothelial nitric oxide production 49) . In combination, activation of the protein kinase Akt by VEGF orchestrates several signalling events that contribute to EC migration and angiogenesis. Our results are in line with these previous observations on the importance of Akt and eNOS in VEGF-stimulated migration 47, 48) .
In addition, we have demonstrated, that exposure to CRP interferes with and inhibits this critical pathway in endothelial cells. We and others reported earlier that the mitogen-activated protein kinases ERK1/2 represent other important signalling molecules that mediate the migration of vascular and nonvascular cells by regulating cytosolic and nuclear signalling events 35, 50, 51) . In this study, we found that blockade of the ERK1/2 pathway leads to inhibition of EC migration in response to VEGF. ERK1/2 have been shown to modulate cell motility through the downstream phosphorylation and activation of myosin light chain kinase. In addition to these cytosolic events, several studies have revealed that cell migration requires ERK1/2-dependent expression and release of matrix metalloproteinases, suggesting the additional involvement of nuclear signalling events 13, 50, 52) . Using inhibitor studies, we were able to show that activation of the Akt eNOS pathway and ERK1/2 phosphorylation occur independently of each other, suggesting two distinct signalling pathways that participate in VEGFinduced endothelial cell migration. In contrast to its effects on the Akt NOS pathway, CRP did not affect the phosphorylation and activation of ERK1/2, which may explain why VEGF-induced migration was only partially inhibited by CRP. Since the lipid phosphatase PTEN is known to antagonize PI3K-mediated phos-phorylation of Akt and thereby inhibits VEGFinduced angiogenesis and migration, we investigated whether CRP affects PTEN protein expression in endothelial cells. In fact, we found that long-term CRP exposure enhances endothelial PTEN protein levels. We also observed that the time course of CRPmediated PTEN induction corresponds with the inhibitory actions of CRP exposure on VEGF-stimulated Akt and eNOS phosphorylation, suggesting a potential role for PTEN in the antimigratory actions of CRP in endothelial cells.
In conclusion, we were able to identify CRP as a potent inhibitor of endothelial cell migration that exerts its antimigratory effect through upregulation of PTEN, which subsequently inhibits cellular signalling via the Akt eNOS pathway. These results provide novel targets for CRP deleterious effects on the vasculature.
